Kinnari Patel - 09 Apr 2025 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)

Role
President, Head of R&D and Chief Operating Officer
Signature
/s/ Martin Wilson, as attorney-in-fact for Kinnari Patel
Issuer symbol
RCKT
Transactions as of
09 Apr 2025
Net transactions value
+$99,165
Form type
4
Filing time
10 Apr 2025, 16:07:53 UTC
Previous filing
25 Feb 2025
Next filing
20 May 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RCKT Common Stock Purchase $99,165 +21,099 +372% $4.70 26,774 09 Apr 2025 By Spouse F1
holding RCKT Common Stock 444,103 09 Apr 2025 Direct F2
holding RCKT Common Stock 104,927 09 Apr 2025 By Adaptive Technology LLC F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On April 9, 2025, the Reporting Person's husband purchased 21,099 shares of Common Stock in a series of brokered transactions at prices ranging from $4.65 to $4.78 and a weighted average price per share of $4.70 (rounded to two decimal places), for an aggregate purchase price of approximately $99,157. The detailed breakdown of executed sales will be furnished upon request.
F2 Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.
F3 The shares are held indirectly through Adaptive Technology, LLC, a limited liability company that is owned and managed by the reporting person's husband.

Remarks:

President, Head of R&D and Chief Operating Officer